Ponesimod (Ponvory) for Multiple Sclerosis

Date: August 9, 2021 Issue #:  1630Summary:  The FDA has approved ponesimod (Ponvory– Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Ponesimod is the fourth oral S1P receptor modulator to be approved in the US for once-daily treatment of relapsing forms of MS; ozanimod(Zeposia) and siponimod(Mayzent) are also approved for use in adults, and fingolimod(Gilenya) is indicated for use in patients ≥10 years old.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research